Sudeep Pharma: Press Release - FDA Approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat
Sudeep Pharma (SUDEEPPHRM) filed a disclosure titled "Press Release - FDA Approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat". The company is valued at about ₹10,907 crore.
What happened
Sudeep Pharma (SUDEEPPHRM) filed a disclosure with the exchanges on 26 October 2026 at 12:31 PM titled "Press Release - FDA Approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat".
Company snapshot
Sudeep Pharma is a small-cap company in the Chemicals sector, with a market value of about ₹10,907 crore.
The stock last traded at ₹965.7, against a 52-week range of ₹524.1–₹1,378 (29.9% below the high).
Before this filing the shares had moved −19.3% over the month and +17.1% over three months. Average daily turnover over the last 20 sessions was about ₹24.22 crore.
Promoters held 76.15% at the end of Q1 FY27. Foreign institutions owned 1.81% and domestic institutions 15.65%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 163 | 45.7 | 4.2 |
| Q3 FY26 | 172 | -2 | 4.29 |
| Q4 FY26 | 182 | 48.9 | 4.38 |
| Q1 FY27 | 158 | 40.6 | 3.59 |
What history shows
BCEIE has no earlier approval filing from this company on record since May 2026.
Across 18 similar disclosures by other Chemicals companies, shares moved +2.0% on average the next day and +1.7% over five days; 67% of them rose the next day.
Market-wide, 1,519 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- 28 October 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.